Keratoacanthoma
☆ Muzotsatira za 2022 Stiftung Warentest zochokera ku Germany, kukhutitsidwa kwa ogula ndi ModelDerm kunali kotsika pang'ono kusiyana ndi kuyankhulana kwa telemedicine komwe kulipiridwa.
Wanthawi Keratoacanthoma
References
Keratoacanthoma (KA) ndi chotupa chapakhungu chomwe chimadziwika kuti chimakula mwachangu komanso chimatha kubwerera chokha. Nthawi zambiri zimachitika mwa amuna achikulire, akhungu loyera omwe adawonongeka ndi dzuwa. Ngakhale kuchotsa maopaleshoni pogwiritsa ntchito mocheka kapena Mohs micrographic ndi chithandizo chanthawi zonse, pali njira zina zochizira zomwe zilipo.
Keratoacanthoma (KA) is a common cutaneous tumor characterized by rapid growth and possible spontaneous regression. It most commonly affects older, fair-skinned males with significantly sun damaged skin. Although surgical removal with excision or Mohs micrographic surgery remains the standard of therapy, there are many alternative therapeutic modalities that can be utilized.
Keratoacanthoma (KA) is a common cutaneous tumor characterized by rapid growth and possible spontaneous regression. It most commonly affects older, fair-skinned males with significantly sun damaged skin. Although surgical removal with excision or Mohs micrographic surgery remains the standard of therapy, there are many alternative therapeutic modalities that can be utilized.
Keratoacanthoma (KA) ndi chotupa chochepa kwambiri chomwe chimayambira m'matumbo ena pakhungu ndipo chimafanana ndi squamous cell carcinoma (SCC) pansi pa maikulosikopu. Pali mkangano wopitilira ngati KA iyenera kusankhidwa ngati mtundu wa SCC wosokoneza.
Keratoacanthoma (KA) is a comparatively common low-grade tumor that initiates in the pilo-sebaceous glands and pathologically mimics squamous cell carcinoma (SCC). Essentially, strong debates confirm classifying keratoacanthoma as a variant of invasive SCC. The clinical behavior of KA is hardly predictable and the differential diagnosis of keratoacanthoma and other conditions with keratoacanthoma-like pseudocarcinomatous epithelial hyperplasia is challenging, both clinically and histopathologically.
Keratoacanthoma (KA) is a comparatively common low-grade tumor that initiates in the pilo-sebaceous glands and pathologically mimics squamous cell carcinoma (SCC). Essentially, strong debates confirm classifying keratoacanthoma as a variant of invasive SCC. The clinical behavior of KA is hardly predictable and the differential diagnosis of keratoacanthoma and other conditions with keratoacanthoma-like pseudocarcinomatous epithelial hyperplasia is challenging, both clinically and histopathologically.
Cutaneous squamous cell carcinoma (cSCC) ndi mtundu wachiwiri wa khansa yodziwika bwino mwa anthu, makamaka pakati pa okalamba. Opaleshoni imagwiritsidwa ntchito pochiza cSCC, koma kwa odwala ena omwe sangathe kuchitidwa opaleshoni kapena osasankha, njira zina monga chithandizo cha intralesional zitha kuganiziridwa. Thandizo lachikale la intralesional (methotrexate or 5-fluorouracil) lakhala likugwiritsidwa ntchito, koma pali kafukufuku wopitilira panjira zatsopano monga intralesional immunotherapy ndi oncolytic virotherapy. M'menemo, tiwona njira zosiyanasiyana zochiritsira za cSCC, kuyambira njira zachikale mpaka njira zotsogola.
Cutaneous squamous cell carcinoma (cSCC) is the second most frequent cancer in humans, and it is especially common in fragile, elderly people. Surgery is the standard treatment for cSCC but intralesional treatments can be an alternative in those patients who are either not candidates or refuse to undergo surgery. Classic intralesional treatments, including methotrexate or 5-fluorouracil, have been implemented, but there is now a landscape of active research to incorporate intralesional immunotherapy and oncolytic virotherapy into the scene, which might change the way we deal with cSCC in the future. In this review, we focus on intralesional treatments for cSCC (including keratoacanthoma), from classic to very novel strategies.
Cutaneous squamous cell carcinoma (cSCC) is the second most frequent cancer in humans, and it is especially common in fragile, elderly people. Surgery is the standard treatment for cSCC but intralesional treatments can be an alternative in those patients who are either not candidates or refuse to undergo surgery. Classic intralesional treatments, including methotrexate or 5-fluorouracil, have been implemented, but there is now a landscape of active research to incorporate intralesional immunotherapy and oncolytic virotherapy into the scene, which might change the way we deal with cSCC in the future. In this review, we focus on intralesional treatments for cSCC (including keratoacanthoma), from classic to very novel strategies.
Pansi pa maikulosikopu, keratoacanthoma imafanana kwambiri ndi squamous cell carcinoma. Ngakhale akatswiri ena amatcha keratoacanthoma ngati chinthu chodziwika bwino osati chowopsa, pafupifupi 6% yazachipatala ndi histological keratoacanthoma zimapita patsogolo ku khansa ya squamous cell yowononga komanso yaukali.
○ Kuzindikira ndi Chithandizo
#Dermoscopy
#Skin biopsy